Deargen (President: Kilsoo Kang), an artificial intelligence (AI)-powered drug discovery and development company, announced that it has signed an agreement with Sookmyung Women’s University Research & Business Development Foundation for licensing biomarker technologies for determining the progression stage of NASH (non-alcoholic steatohepatitis) patients. Proprietary biomarker technologies licensed by Deargen from Sookmyung Women’s University Research & Business Development Foundation can...
